自己免疫薬の世界市場

自己免疫薬の世界市場は2030年までに1,256億米ドルに到達

2024年に911億米ドルと推定される自己免疫薬の世界市場は、2024～2030年の分析期間においてCAGR 5.5%で成長し、2030年には1,256億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである関節リウマチは、CAGR 6.6%を記録し、分析期間終了時には540億米ドルに達すると予測されます。多発性硬化症分野の成長率は、分析期間中CAGR 3.9%と推定されます。

米国市場は248億米ドルと推定、中国はCAGR 8.9％で成長予測

米国の自己免疫薬市場は2024年に248億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに255億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは8.9%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ2.6%と5.5%と予測されています。欧州では、ドイツがCAGR 3.6%で成長すると予測されています。

世界の自己免疫薬市場- 主要動向と促進要因まとめ

今日、自己免疫疾患が医薬品の中で大きなシェアを占めているのはなぜか？

かつては比較的まれな疾患と考えられていた自己免疫疾患は、その罹患率の上昇と慢性的な性質により、現在では世界的に関心が高まっています。関節リウマチ、多発性硬化症、ループス、1型糖尿病、炎症性腸疾患などの開発は、特に先進国においてより一般的になりつつあります。この急増は、遺伝的素因、環境因子、食生活の変化、都市汚染、生活習慣のストレス要因などが複雑に絡み合い、免疫調節を総体的に乱すことに起因しています。これらの疾患に対する認識が高まるにつれて、早期診断が可能となり、より多くの患者が治療の対象となります。さらに、多くの自己免疫疾患は、特に生殖年齢にある女性に不釣り合いに影響を及ぼし、社会的およびヘルスケアへの影響を増幅させています。このため、症状を管理し、再燃を抑え、疾患の進行を最小限に抑える長期的な治療ソリューションが急務となっています。製薬業界はこれに注目し、自己免疫疾患治療薬の研究に多額の投資を行っています。さらに、多くの自己免疫疾患は慢性疾患に分類され、生涯にわたる管理が必要であることから、効果的な治療薬に対する安定的かつ継続的な需要が確保され、この市場は医薬品メーカーにとって戦略的に重要なセグメントとなっています。

生物学的製剤と標的療法は治療成績をどのように変えているか？

自己免疫疾患の治療パラダイムは、生物学的製剤と標的低分子治療薬の登場によって激変しました。免疫応答を広範囲に抑制する従来の免疫抑制剤とは異なり、生物学的製剤（TNF阻害剤、IL-6遮断剤、B細胞モジュレーターなど）は免疫シグナル伝達経路により正確に介入します。これにより、寛解期間の延長、副作用の軽減、QOLの改善など、患者の予後が大幅に改善しました。アダリムマブ、エタネルセプト、リツキシマブのような薬剤は、関節リウマチや他の全身性自己免疫疾患の治療の主役となっています。一方、JAK阻害剤やS1P受容体モジュレーターは、強力な有効性プロファイルを有する新規の経口代替薬を提供しています。バイオシミラーもまた、特にコストに敏感な市場において、治療価値を損なうことなく医薬品へのアクセスを向上させる役割を果たすようになってきています。自動注射器や装着型輸液デバイスなどのドラッグデリバリーの革新により、治療のアドヒアランスはさらに向上しています。パイプラインには、治療をさらに個別化することが期待される新しい免疫調節薬や併用療法が豊富にあります。これらの科学的・臨床的進歩は、自己免疫薬市場を拡大させただけでなく、疾患のコントロールと寛解に対する期待をリセットしています。

ヘルスケアへのアクセスと患者支持は市場の勢いを促進するか？

ヘルスケアサービスへのアクセスの向上、保険適用の拡大、患者アドボカシーの強化は、世界中で自己免疫薬の普及を加速させる上で極めて重要です。高所得国では、体系化された償還スキームと統合ケアモデルにより、より早期の診断、定期的なモニタリング、高度な治療のタイムリーな開始が可能になっています。遠隔医療プラットフォームやデジタルヘルスツールも、特に遠隔地や十分な医療を受けられない地域の患者にとって、継続的なケアを可能にしています。一方、アドボカシーグループや患者コミュニティは強力な利害関係者となり、認知度の向上、研究資金の提供、国の必須医薬品リストへの自己免疫薬の掲載を推進しています。特に米国では、消費者向けの医薬品直販広告も、患者が専門医の治療を受けたり、治療に関する話し合いを始めたりできるようにする上で一役買っています。新興国においては、コストが依然として障壁となっているもの、中産階級の人口増加や公衆衛生改革により、医薬品へのアクセスは着実に改善されています。また、政府、NGO、製薬企業間の国際的な協力により、負担の大きい自己免疫疾患に対する治療助成プログラムも進んでいます。こうした努力の正味の成果は、治療の開始と継続の大幅な増加であり、市場の成長に直結しています。

自己免疫薬市場の成長は複数の要因によってもたらされる...

自己免疫薬市場の成長を後押ししているのは、医療、技術、社会の力学が複雑に絡み合った複数の動向です。第一に、免疫学とゲノム・プロファイリングの進歩により、特異性の高い標的治療薬の開発が可能になりました。第二に、希少な自己免疫疾患や診断の遅れている自己免疫疾患に対する臨床研究の拡大により、新たな患者層が治療の対象となりました。第三に、診断ツールやバイオマーカーの改善により早期発見が可能になり、薬物治療の対象となる患者数が増加しました。第4に、専門クリニックや輸液センターの増加により、複雑な生物学的製剤治療へのアクセスが合理化され、治療の遅れや脱落率が減少しました。第五に、健康リテラシーの向上により、慢性疾患管理に対する消費者の期待が変化し、オーダーメイドの長期的治療計画に対する需要が高まっています。第六に、製薬会社は自己免疫疾患に特化した次世代生物製剤、経口剤、遺伝子治療薬などのパイプライン開発に積極的に投資しています。最後に、世界の人口動態の変化、特に免疫異常を悪化させる高齢化社会と都市型ライフスタイルが自己免疫疾患の発症率を高め、市場の裾野を広げています。科学的イノベーション、ヘルスケアインフラ、患者エンゲージメントに根ざしたこれらの市場促進要因は、自己免疫薬市場を急速なペースで前進させ続けています。

セグメント

治療領域（関節リウマチ、多発性硬化症、乾癬、炎症性腸疾患、その他の治療領域）、流通チャネル（病院流通チャネル、薬局流通チャネル、ドラッグストア／小売薬局流通チャネル、オンライン流通チャネル）

調査対象企業の例（全41件）

• AbbVie Inc.
• AdvaCare Pharma
• Amgen Inc.
• Anthera Pharmaceuticals
• AstraZeneca plc
• Bayer AG
• Biogen Inc.
• BioNTech SE
• Bristol-Myers Squibb Company
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd
• Genmab A/S
• Gilead Sciences, Inc.
• GlaxoSmithKline plc
• Halozyme Therapeutics, Inc.
• Intellia Therapeutics, Inc.
• Johnson & Johnson
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.
• Regeneron Pharmaceuticals
• Sanofi S.A.
• UCB S.A.
• Zymeworks Inc.

AI統合

私たちは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Autoimmune Drugs Market to Reach US$125.6 Billion by 2030

The global market for Autoimmune Drugs estimated at US$91.1 Billion in the year 2024, is expected to reach US$125.6 Billion by 2030, growing at a CAGR of 5.5% over the analysis period 2024-2030. Rheumatoid Arthritis, one of the segments analyzed in the report, is expected to record a 6.6% CAGR and reach US$54.0 Billion by the end of the analysis period. Growth in the Multiple Sclerosis segment is estimated at 3.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$24.8 Billion While China is Forecast to Grow at 8.9% CAGR

The Autoimmune Drugs market in the U.S. is estimated at US$24.8 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$25.5 Billion by the year 2030 trailing a CAGR of 8.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.6% and 5.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.6% CAGR.

Global Autoimmune Drugs Market - Key Trends & Drivers Summarized

Why Are Autoimmune Diseases Commanding a Larger Share of Pharmaceutical Focus Today?

Autoimmune diseases, once considered relatively rare, are now a growing concern globally due to their rising incidence and chronic nature. Conditions such as rheumatoid arthritis, multiple sclerosis, lupus, type 1 diabetes, and inflammatory bowel disease are becoming more prevalent, especially in developed nations. This surge is attributed to a complex interplay of genetic predisposition, environmental factors, changes in diet, urban pollution, and lifestyle stressors that collectively disrupt immune regulation. As awareness of these diseases increases, so does early diagnosis, bringing more patients into the treatment pipeline. Furthermore, many autoimmune conditions disproportionately affect women, particularly in their reproductive years, amplifying their societal and healthcare impact. This has led to an urgent demand for long-term treatment solutions that manage symptoms, reduce flares, and minimize disease progression. The pharmaceutical industry has taken note, channeling significant investment into autoimmune drug research. Additionally, with many autoimmune conditions classified as chronic, the need for lifelong management ensures a stable and recurring demand for effective therapeutics, making this market a strategically important segment for drug manufacturers.

How Are Biologics and Targeted Therapies Reshaping Treatment Outcomes?

The treatment paradigm for autoimmune disorders has undergone a radical transformation with the emergence of biologics and targeted small molecule therapies. Unlike traditional immunosuppressants, which broadly dampen immune responses, biologics-such as TNF inhibitors, IL-6 blockers, and B-cell modulators-intervene more precisely in the immune signaling pathways. This has led to significant improvements in patient outcomes, including longer remission periods, fewer side effects, and improved quality of life. Drugs like adalimumab, etanercept, and rituximab have become mainstays in managing rheumatoid arthritis and other systemic autoimmune conditions. Meanwhile, JAK inhibitors and S1P receptor modulators are providing novel oral alternatives with robust efficacy profiles. Biosimilars are also playing a growing role, particularly in cost-sensitive markets, enhancing access without compromising therapeutic value. Innovations in drug delivery-such as auto-injectors and wearable infusion devices-have further improved treatment adherence. The pipeline is rich with new immunomodulators and combination therapies that promise to further personalize treatment. These scientific and clinical advances have not only expanded the autoimmune drugs market but have also reset expectations around disease control and remission.

Could Healthcare Access and Patient Advocacy Be Driving Market Momentum?

Greater access to healthcare services, increased insurance coverage, and stronger patient advocacy are pivotal in accelerating the uptake of autoimmune drugs worldwide. In high-income countries, structured reimbursement schemes and integrated care models allow for earlier diagnosis, regular monitoring, and timely initiation of advanced therapies. Telemedicine platforms and digital health tools are also enabling continuous care, especially for patients in remote or underserved areas. Meanwhile, advocacy groups and patient communities have become powerful stakeholders, pushing for better awareness, research funding, and inclusion of autoimmune drugs in national essential medicines lists. Direct-to-consumer pharmaceutical advertising, especially in the U.S., has also played a role in empowering patients to seek specialist care and initiate treatment discussions. In emerging economies, although cost remains a barrier, growing middle-class populations and public health reforms are steadily improving drug accessibility. International collaborations between governments, NGOs, and pharmaceutical companies are also leading to subsidized treatment programs for high-burden autoimmune diseases. The net result of these efforts is a significant increase in treatment initiation and continuity, feeding directly into market growth.

The Growth in the Autoimmune Drugs Market Is Driven by Several Factors…

Multiple converging trends are fueling the growth of the autoimmune drugs market, with each factor reinforcing the other in a complex web of medical, technological, and societal dynamics. First, advances in immunology and genomic profiling have enabled the development of highly specific, targeted therapies that offer superior efficacy with fewer off-target effects. Second, the expansion of clinical research into rare and underdiagnosed autoimmune diseases has brought new patient segments into the treatment spectrum. Third, improved diagnostic tools and biomarkers have led to earlier detection, thereby increasing the pool of patients eligible for pharmaceutical intervention. Fourth, the rising number of specialty clinics and infusion centers has streamlined access to complex biologic therapies, reducing delays and dropout rates. Fifth, shifting consumer expectations around chronic disease management, driven by a more health-literate public, have increased demand for tailored and long-term treatment plans. Sixth, pharmaceutical companies are aggressively investing in pipeline development, including next-generation biologics, oral agents, and gene therapies specifically aimed at autoimmune conditions. Lastly, global demographic changes, particularly aging populations and urban lifestyles that exacerbate immune dysregulation, are increasing the incidence of autoimmune diseases, thus expanding the market’s base. These growth drivers, grounded in scientific innovation, healthcare infrastructure, and patient engagement, continue to propel the autoimmune drugs market forward at a rapid pace.

SCOPE OF STUDY:

The report analyzes the Autoimmune Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Therapy Area (Rheumatoid Arthritis, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease, Other Therapy Areas); Distribution Channel (Hospitals Distribution Channel, Pharmacies Distribution Channel, Drug Stores / Retail Pharmacy Distribution Channel, Online Distribution Channel)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 41 Featured) -

• AbbVie Inc.
• AdvaCare Pharma
• Amgen Inc.
• Anthera Pharmaceuticals
• AstraZeneca plc
• Bayer AG
• Biogen Inc.
• BioNTech SE
• Bristol-Myers Squibb Company
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd
• Genmab A/S
• Gilead Sciences, Inc.
• GlaxoSmithKline plc
• Halozyme Therapeutics, Inc.
• Intellia Therapeutics, Inc.
• Johnson & Johnson
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.
• Regeneron Pharmaceuticals
• Sanofi S.A.
• UCB S.A.
• Zymeworks Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Tariff Impact on Global Supply Chain Patterns
  • Autoimmune Drugs - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Incidence of Autoimmune Disorders Propels Drug Development Pipelines
  • Increased R&D Investment by Biopharma Players Spurs Innovation in Treatment Classes
  • Patient Demand for Targeted Therapies Drives Growth of Biologics and Biosimilars
  • Expansion of Precision Medicine Initiatives Strengthens Case for Personalized Autoimmune Treatments
  • Accelerated Drug Approvals by Regulatory Bodies Open New Market Opportunities
  • Shift Toward Oral Small Molecule Drugs Enhances Treatment Adherence and Uptake
  • Increasing Use of Companion Diagnostics Boosts Market for Personalized Immunotherapies
  • Expansion of Telehealth and Digital Patient Engagement Supports Long-Term Drug Adoption
  • Strategic Collaborations and M&A Activities Fuel Innovation and Portfolio Diversification
  • Chronic Nature of Autoimmune Conditions Ensures Sustained Demand for Long-Term Therapies
  • Launch of First-in-Class Therapies Generates Buzz and Drives Early Adoption
  • Strong Clinical Pipeline of Novel Immunomodulators Expands Future Market Landscape
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Autoimmune Drugs Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Autoimmune Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Autoimmune Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 4: World 16-Year Perspective for Autoimmune Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Rheumatoid Arthritis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Rheumatoid Arthritis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 7: World 16-Year Perspective for Rheumatoid Arthritis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Multiple Sclerosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Multiple Sclerosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 10: World 16-Year Perspective for Multiple Sclerosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Psoriasis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Psoriasis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 13: World 16-Year Perspective for Psoriasis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Inflammatory Bowel Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Inflammatory Bowel Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 16: World 16-Year Perspective for Inflammatory Bowel Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Other Therapy Areas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Other Therapy Areas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 19: World 16-Year Perspective for Other Therapy Areas by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Hospitals Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Hospitals Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 22: World 16-Year Perspective for Hospitals Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 25: World 16-Year Perspective for Pharmacies Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Drug Stores / Retail Pharmacy Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Drug Stores / Retail Pharmacy Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 28: World 16-Year Perspective for Drug Stores / Retail Pharmacy Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 31: World 16-Year Perspective for Online Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Autoimmune Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 32: USA Recent Past, Current & Future Analysis for Autoimmune Drugs by Therapy Area - Rheumatoid Arthritis, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Therapy Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 33: USA Historic Review for Autoimmune Drugs by Therapy Area - Rheumatoid Arthritis, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Therapy Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 34: USA 16-Year Perspective for Autoimmune Drugs by Therapy Area - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Therapy Areas for the Years 2014, 2025 & 2030
  • TABLE 35: USA Recent Past, Current & Future Analysis for Autoimmune Drugs by Distribution Channel - Hospitals Distribution Channel, Pharmacies Distribution Channel, Drug Stores / Retail Pharmacy Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 36: USA Historic Review for Autoimmune Drugs by Distribution Channel - Hospitals Distribution Channel, Pharmacies Distribution Channel, Drug Stores / Retail Pharmacy Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 37: USA 16-Year Perspective for Autoimmune Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Distribution Channel, Pharmacies Distribution Channel, Drug Stores / Retail Pharmacy Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
• CANADA
  • TABLE 38: Canada Recent Past, Current & Future Analysis for Autoimmune Drugs by Therapy Area - Rheumatoid Arthritis, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Therapy Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 39: Canada Historic Review for Autoimmune Drugs by Therapy Area - Rheumatoid Arthritis, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Therapy Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 40: Canada 16-Year Perspective for Autoimmune Drugs by Therapy Area - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Therapy Areas for the Years 2014, 2025 & 2030
  • TABLE 41: Canada Recent Past, Current & Future Analysis for Autoimmune Drugs by Distribution Channel - Hospitals Distribution Channel, Pharmacies Distribution Channel, Drug Stores / Retail Pharmacy Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 42: Canada Historic Review for Autoimmune Drugs by Distribution Channel - Hospitals Distribution Channel, Pharmacies Distribution Channel, Drug Stores / Retail Pharmacy Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 43: Canada 16-Year Perspective for Autoimmune Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Distribution Channel, Pharmacies Distribution Channel, Drug Stores / Retail Pharmacy Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
• JAPAN
  • Autoimmune Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 44: Japan Recent Past, Current & Future Analysis for Autoimmune Drugs by Therapy Area - Rheumatoid Arthritis, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Therapy Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: Japan Historic Review for Autoimmune Drugs by Therapy Area - Rheumatoid Arthritis, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Therapy Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 46: Japan 16-Year Perspective for Autoimmune Drugs by Therapy Area - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Therapy Areas for the Years 2014, 2025 & 2030
  • TABLE 47: Japan Recent Past, Current & Future Analysis for Autoimmune Drugs by Distribution Channel - Hospitals Distribution Channel, Pharmacies Distribution Channel, Drug Stores / Retail Pharmacy Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 48: Japan Historic Review for Autoimmune Drugs by Distribution Channel - Hospitals Distribution Channel, Pharmacies Distribution Channel, Drug Stores / Retail Pharmacy Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 49: Japan 16-Year Perspective for Autoimmune Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Distribution Channel, Pharmacies Distribution Channel, Drug Stores / Retail Pharmacy Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
• CHINA
  • Autoimmune Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 50: China Recent Past, Current & Future Analysis for Autoimmune Drugs by Therapy Area - Rheumatoid Arthritis, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Therapy Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: China Historic Review for Autoimmune Drugs by Therapy Area - Rheumatoid Arthritis, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Therapy Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 52: China 16-Year Perspective for Autoimmune Drugs by Therapy Area - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Therapy Areas for the Years 2014, 2025 & 2030
  • TABLE 53: China Recent Past, Current & Future Analysis for Autoimmune Drugs by Distribution Channel - Hospitals Distribution Channel, Pharmacies Distribution Channel, Drug Stores / Retail Pharmacy Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: China Historic Review for Autoimmune Drugs by Distribution Channel - Hospitals Distribution Channel, Pharmacies Distribution Channel, Drug Stores / Retail Pharmacy Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 55: China 16-Year Perspective for Autoimmune Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Distribution Channel, Pharmacies Distribution Channel, Drug Stores / Retail Pharmacy Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
• EUROPE
  • Autoimmune Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 56: Europe Recent Past, Current & Future Analysis for Autoimmune Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 57: Europe Historic Review for Autoimmune Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 58: Europe 16-Year Perspective for Autoimmune Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
  • TABLE 59: Europe Recent Past, Current & Future Analysis for Autoimmune Drugs by Therapy Area - Rheumatoid Arthritis, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Therapy Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Europe Historic Review for Autoimmune Drugs by Therapy Area - Rheumatoid Arthritis, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Therapy Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 61: Europe 16-Year Perspective for Autoimmune Drugs by Therapy Area - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Therapy Areas for the Years 2014, 2025 & 2030
  • TABLE 62: Europe Recent Past, Current & Future Analysis for Autoimmune Drugs by Distribution Channel - Hospitals Distribution Channel, Pharmacies Distribution Channel, Drug Stores / Retail Pharmacy Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Europe Historic Review for Autoimmune Drugs by Distribution Channel - Hospitals Distribution Channel, Pharmacies Distribution Channel, Drug Stores / Retail Pharmacy Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 64: Europe 16-Year Perspective for Autoimmune Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Distribution Channel, Pharmacies Distribution Channel, Drug Stores / Retail Pharmacy Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
• FRANCE
  • Autoimmune Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 65: France Recent Past, Current & Future Analysis for Autoimmune Drugs by Therapy Area - Rheumatoid Arthritis, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Therapy Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: France Historic Review for Autoimmune Drugs by Therapy Area - Rheumatoid Arthritis, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Therapy Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 67: France 16-Year Perspective for Autoimmune Drugs by Therapy Area - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Therapy Areas for the Years 2014, 2025 & 2030
  • TABLE 68: France Recent Past, Current & Future Analysis for Autoimmune Drugs by Distribution Channel - Hospitals Distribution Channel, Pharmacies Distribution Channel, Drug Stores / Retail Pharmacy Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: France Historic Review for Autoimmune Drugs by Distribution Channel - Hospitals Distribution Channel, Pharmacies Distribution Channel, Drug Stores / Retail Pharmacy Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 70: France 16-Year Perspective for Autoimmune Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Distribution Channel, Pharmacies Distribution Channel, Drug Stores / Retail Pharmacy Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
• GERMANY
  • Autoimmune Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 71: Germany Recent Past, Current & Future Analysis for Autoimmune Drugs by Therapy Area - Rheumatoid Arthritis, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Therapy Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Germany Historic Review for Autoimmune Drugs by Therapy Area - Rheumatoid Arthritis, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Therapy Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 73: Germany 16-Year Perspective for Autoimmune Drugs by Therapy Area - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Therapy Areas for the Years 2014, 2025 & 2030
  • TABLE 74: Germany Recent Past, Current & Future Analysis for Autoimmune Drugs by Distribution Channel - Hospitals Distribution Channel, Pharmacies Distribution Channel, Drug Stores / Retail Pharmacy Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Germany Historic Review for Autoimmune Drugs by Distribution Channel - Hospitals Distribution Channel, Pharmacies Distribution Channel, Drug Stores / Retail Pharmacy Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 76: Germany 16-Year Perspective for Autoimmune Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Distribution Channel, Pharmacies Distribution Channel, Drug Stores / Retail Pharmacy Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
• ITALY
  • TABLE 77: Italy Recent Past, Current & Future Analysis for Autoimmune Drugs by Therapy Area - Rheumatoid Arthritis, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Therapy Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Italy Historic Review for Autoimmune Drugs by Therapy Area - Rheumatoid Arthritis, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Therapy Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 79: Italy 16-Year Perspective for Autoimmune Drugs by Therapy Area - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Therapy Areas for the Years 2014, 2025 & 2030
  • TABLE 80: Italy Recent Past, Current & Future Analysis for Autoimmune Drugs by Distribution Channel - Hospitals Distribution Channel, Pharmacies Distribution Channel, Drug Stores / Retail Pharmacy Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Italy Historic Review for Autoimmune Drugs by Distribution Channel - Hospitals Distribution Channel, Pharmacies Distribution Channel, Drug Stores / Retail Pharmacy Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 82: Italy 16-Year Perspective for Autoimmune Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Distribution Channel, Pharmacies Distribution Channel, Drug Stores / Retail Pharmacy Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
• UNITED KINGDOM
  • Autoimmune Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 83: UK Recent Past, Current & Future Analysis for Autoimmune Drugs by Therapy Area - Rheumatoid Arthritis, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Therapy Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: UK Historic Review for Autoimmune Drugs by Therapy Area - Rheumatoid Arthritis, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Therapy Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 85: UK 16-Year Perspective for Autoimmune Drugs by Therapy Area - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Therapy Areas for the Years 2014, 2025 & 2030
  • TABLE 86: UK Recent Past, Current & Future Analysis for Autoimmune Drugs by Distribution Channel - Hospitals Distribution Channel, Pharmacies Distribution Channel, Drug Stores / Retail Pharmacy Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: UK Historic Review for Autoimmune Drugs by Distribution Channel - Hospitals Distribution Channel, Pharmacies Distribution Channel, Drug Stores / Retail Pharmacy Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 88: UK 16-Year Perspective for Autoimmune Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Distribution Channel, Pharmacies Distribution Channel, Drug Stores / Retail Pharmacy Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
• SPAIN
  • TABLE 89: Spain Recent Past, Current & Future Analysis for Autoimmune Drugs by Therapy Area - Rheumatoid Arthritis, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Therapy Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Spain Historic Review for Autoimmune Drugs by Therapy Area - Rheumatoid Arthritis, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Therapy Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 91: Spain 16-Year Perspective for Autoimmune Drugs by Therapy Area - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Therapy Areas for the Years 2014, 2025 & 2030
  • TABLE 92: Spain Recent Past, Current & Future Analysis for Autoimmune Drugs by Distribution Channel - Hospitals Distribution Channel, Pharmacies Distribution Channel, Drug Stores / Retail Pharmacy Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Spain Historic Review for Autoimmune Drugs by Distribution Channel - Hospitals Distribution Channel, Pharmacies Distribution Channel, Drug Stores / Retail Pharmacy Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 94: Spain 16-Year Perspective for Autoimmune Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Distribution Channel, Pharmacies Distribution Channel, Drug Stores / Retail Pharmacy Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
• RUSSIA
  • TABLE 95: Russia Recent Past, Current & Future Analysis for Autoimmune Drugs by Therapy Area - Rheumatoid Arthritis, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Therapy Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Russia Historic Review for Autoimmune Drugs by Therapy Area - Rheumatoid Arthritis, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Therapy Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 97: Russia 16-Year Perspective for Autoimmune Drugs by Therapy Area - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Therapy Areas for the Years 2014, 2025 & 2030
  • TABLE 98: Russia Recent Past, Current & Future Analysis for Autoimmune Drugs by Distribution Channel - Hospitals Distribution Channel, Pharmacies Distribution Channel, Drug Stores / Retail Pharmacy Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Russia Historic Review for Autoimmune Drugs by Distribution Channel - Hospitals Distribution Channel, Pharmacies Distribution Channel, Drug Stores / Retail Pharmacy Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 100: Russia 16-Year Perspective for Autoimmune Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Distribution Channel, Pharmacies Distribution Channel, Drug Stores / Retail Pharmacy Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
• REST OF EUROPE
  • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Autoimmune Drugs by Therapy Area - Rheumatoid Arthritis, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Therapy Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Rest of Europe Historic Review for Autoimmune Drugs by Therapy Area - Rheumatoid Arthritis, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Therapy Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 103: Rest of Europe 16-Year Perspective for Autoimmune Drugs by Therapy Area - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Therapy Areas for the Years 2014, 2025 & 2030
  • TABLE 104: Rest of Europe Recent Past, Current & Future Analysis for Autoimmune Drugs by Distribution Channel - Hospitals Distribution Channel, Pharmacies Distribution Channel, Drug Stores / Retail Pharmacy Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Rest of Europe Historic Review for Autoimmune Drugs by Distribution Channel - Hospitals Distribution Channel, Pharmacies Distribution Channel, Drug Stores / Retail Pharmacy Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 106: Rest of Europe 16-Year Perspective for Autoimmune Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Distribution Channel, Pharmacies Distribution Channel, Drug Stores / Retail Pharmacy Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
• ASIA-PACIFIC
  • Autoimmune Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Autoimmune Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 108: Asia-Pacific Historic Review for Autoimmune Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 109: Asia-Pacific 16-Year Perspective for Autoimmune Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
  • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Autoimmune Drugs by Therapy Area - Rheumatoid Arthritis, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Therapy Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Asia-Pacific Historic Review for Autoimmune Drugs by Therapy Area - Rheumatoid Arthritis, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Therapy Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 112: Asia-Pacific 16-Year Perspective for Autoimmune Drugs by Therapy Area - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Therapy Areas for the Years 2014, 2025 & 2030
  • TABLE 113: Asia-Pacific Recent Past, Current & Future Analysis for Autoimmune Drugs by Distribution Channel - Hospitals Distribution Channel, Pharmacies Distribution Channel, Drug Stores / Retail Pharmacy Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Asia-Pacific Historic Review for Autoimmune Drugs by Distribution Channel - Hospitals Distribution Channel, Pharmacies Distribution Channel, Drug Stores / Retail Pharmacy Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 115: Asia-Pacific 16-Year Perspective for Autoimmune Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Distribution Channel, Pharmacies Distribution Channel, Drug Stores / Retail Pharmacy Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
• AUSTRALIA
  • Autoimmune Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 116: Australia Recent Past, Current & Future Analysis for Autoimmune Drugs by Therapy Area - Rheumatoid Arthritis, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Therapy Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Australia Historic Review for Autoimmune Drugs by Therapy Area - Rheumatoid Arthritis, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Therapy Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 118: Australia 16-Year Perspective for Autoimmune Drugs by Therapy Area - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Therapy Areas for the Years 2014, 2025 & 2030
  • TABLE 119: Australia Recent Past, Current & Future Analysis for Autoimmune Drugs by Distribution Channel - Hospitals Distribution Channel, Pharmacies Distribution Channel, Drug Stores / Retail Pharmacy Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Australia Historic Review for Autoimmune Drugs by Distribution Channel - Hospitals Distribution Channel, Pharmacies Distribution Channel, Drug Stores / Retail Pharmacy Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 121: Australia 16-Year Perspective for Autoimmune Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Distribution Channel, Pharmacies Distribution Channel, Drug Stores / Retail Pharmacy Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
• INDIA
  • Autoimmune Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 122: India Recent Past, Current & Future Analysis for Autoimmune Drugs by Therapy Area - Rheumatoid Arthritis, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Therapy Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: India Historic Review for Autoimmune Drugs by Therapy Area - Rheumatoid Arthritis, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Therapy Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 124: India 16-Year Perspective for Autoimmune Drugs by Therapy Area - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Therapy Areas for the Years 2014, 2025 & 2030
  • TABLE 125: India Recent Past, Current & Future Analysis for Autoimmune Drugs by Distribution Channel - Hospitals Distribution Channel, Pharmacies Distribution Channel, Drug Stores / Retail Pharmacy Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: India Historic Review for Autoimmune Drugs by Distribution Channel - Hospitals Distribution Channel, Pharmacies Distribution Channel, Drug Stores / Retail Pharmacy Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 127: India 16-Year Perspective for Autoimmune Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Distribution Channel, Pharmacies Distribution Channel, Drug Stores / Retail Pharmacy Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
• SOUTH KOREA
  • TABLE 128: South Korea Recent Past, Current & Future Analysis for Autoimmune Drugs by Therapy Area - Rheumatoid Arthritis, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Therapy Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: South Korea Historic Review for Autoimmune Drugs by Therapy Area - Rheumatoid Arthritis, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Therapy Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 130: South Korea 16-Year Perspective for Autoimmune Drugs by Therapy Area - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Therapy Areas for the Years 2014, 2025 & 2030
  • TABLE 131: South Korea Recent Past, Current & Future Analysis for Autoimmune Drugs by Distribution Channel - Hospitals Distribution Channel, Pharmacies Distribution Channel, Drug Stores / Retail Pharmacy Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: South Korea Historic Review for Autoimmune Drugs by Distribution Channel - Hospitals Distribution Channel, Pharmacies Distribution Channel, Drug Stores / Retail Pharmacy Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 133: South Korea 16-Year Perspective for Autoimmune Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Distribution Channel, Pharmacies Distribution Channel, Drug Stores / Retail Pharmacy Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Autoimmune Drugs by Therapy Area - Rheumatoid Arthritis, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Therapy Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Rest of Asia-Pacific Historic Review for Autoimmune Drugs by Therapy Area - Rheumatoid Arthritis, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Therapy Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 136: Rest of Asia-Pacific 16-Year Perspective for Autoimmune Drugs by Therapy Area - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Therapy Areas for the Years 2014, 2025 & 2030
  • TABLE 137: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Autoimmune Drugs by Distribution Channel - Hospitals Distribution Channel, Pharmacies Distribution Channel, Drug Stores / Retail Pharmacy Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Rest of Asia-Pacific Historic Review for Autoimmune Drugs by Distribution Channel - Hospitals Distribution Channel, Pharmacies Distribution Channel, Drug Stores / Retail Pharmacy Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 139: Rest of Asia-Pacific 16-Year Perspective for Autoimmune Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Distribution Channel, Pharmacies Distribution Channel, Drug Stores / Retail Pharmacy Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
• LATIN AMERICA
  • Autoimmune Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 140: Latin America Recent Past, Current & Future Analysis for Autoimmune Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 141: Latin America Historic Review for Autoimmune Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 142: Latin America 16-Year Perspective for Autoimmune Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
  • TABLE 143: Latin America Recent Past, Current & Future Analysis for Autoimmune Drugs by Therapy Area - Rheumatoid Arthritis, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Therapy Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Latin America Historic Review for Autoimmune Drugs by Therapy Area - Rheumatoid Arthritis, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Therapy Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 145: Latin America 16-Year Perspective for Autoimmune Drugs by Therapy Area - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Therapy Areas for the Years 2014, 2025 & 2030
  • TABLE 146: Latin America Recent Past, Current & Future Analysis for Autoimmune Drugs by Distribution Channel - Hospitals Distribution Channel, Pharmacies Distribution Channel, Drug Stores / Retail Pharmacy Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Latin America Historic Review for Autoimmune Drugs by Distribution Channel - Hospitals Distribution Channel, Pharmacies Distribution Channel, Drug Stores / Retail Pharmacy Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 148: Latin America 16-Year Perspective for Autoimmune Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Distribution Channel, Pharmacies Distribution Channel, Drug Stores / Retail Pharmacy Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
• ARGENTINA
  • TABLE 149: Argentina Recent Past, Current & Future Analysis for Autoimmune Drugs by Therapy Area - Rheumatoid Arthritis, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Therapy Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Argentina Historic Review for Autoimmune Drugs by Therapy Area - Rheumatoid Arthritis, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Therapy Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 151: Argentina 16-Year Perspective for Autoimmune Drugs by Therapy Area - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Therapy Areas for the Years 2014, 2025 & 2030
  • TABLE 152: Argentina Recent Past, Current & Future Analysis for Autoimmune Drugs by Distribution Channel - Hospitals Distribution Channel, Pharmacies Distribution Channel, Drug Stores / Retail Pharmacy Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Argentina Historic Review for Autoimmune Drugs by Distribution Channel - Hospitals Distribution Channel, Pharmacies Distribution Channel, Drug Stores / Retail Pharmacy Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 154: Argentina 16-Year Perspective for Autoimmune Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Distribution Channel, Pharmacies Distribution Channel, Drug Stores / Retail Pharmacy Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
• BRAZIL
  • TABLE 155: Brazil Recent Past, Current & Future Analysis for Autoimmune Drugs by Therapy Area - Rheumatoid Arthritis, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Therapy Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Brazil Historic Review for Autoimmune Drugs by Therapy Area - Rheumatoid Arthritis, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Therapy Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 157: Brazil 16-Year Perspective for Autoimmune Drugs by Therapy Area - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Therapy Areas for the Years 2014, 2025 & 2030
  • TABLE 158: Brazil Recent Past, Current & Future Analysis for Autoimmune Drugs by Distribution Channel - Hospitals Distribution Channel, Pharmacies Distribution Channel, Drug Stores / Retail Pharmacy Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Brazil Historic Review for Autoimmune Drugs by Distribution Channel - Hospitals Distribution Channel, Pharmacies Distribution Channel, Drug Stores / Retail Pharmacy Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 160: Brazil 16-Year Perspective for Autoimmune Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Distribution Channel, Pharmacies Distribution Channel, Drug Stores / Retail Pharmacy Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
• MEXICO
  • TABLE 161: Mexico Recent Past, Current & Future Analysis for Autoimmune Drugs by Therapy Area - Rheumatoid Arthritis, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Therapy Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Mexico Historic Review for Autoimmune Drugs by Therapy Area - Rheumatoid Arthritis, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Therapy Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 163: Mexico 16-Year Perspective for Autoimmune Drugs by Therapy Area - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Therapy Areas for the Years 2014, 2025 & 2030
  • TABLE 164: Mexico Recent Past, Current & Future Analysis for Autoimmune Drugs by Distribution Channel - Hospitals Distribution Channel, Pharmacies Distribution Channel, Drug Stores / Retail Pharmacy Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Mexico Historic Review for Autoimmune Drugs by Distribution Channel - Hospitals Distribution Channel, Pharmacies Distribution Channel, Drug Stores / Retail Pharmacy Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 166: Mexico 16-Year Perspective for Autoimmune Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Distribution Channel, Pharmacies Distribution Channel, Drug Stores / Retail Pharmacy Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Autoimmune Drugs by Therapy Area - Rheumatoid Arthritis, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Therapy Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Rest of Latin America Historic Review for Autoimmune Drugs by Therapy Area - Rheumatoid Arthritis, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Therapy Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 169: Rest of Latin America 16-Year Perspective for Autoimmune Drugs by Therapy Area - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Therapy Areas for the Years 2014, 2025 & 2030
  • TABLE 170: Rest of Latin America Recent Past, Current & Future Analysis for Autoimmune Drugs by Distribution Channel - Hospitals Distribution Channel, Pharmacies Distribution Channel, Drug Stores / Retail Pharmacy Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Rest of Latin America Historic Review for Autoimmune Drugs by Distribution Channel - Hospitals Distribution Channel, Pharmacies Distribution Channel, Drug Stores / Retail Pharmacy Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 172: Rest of Latin America 16-Year Perspective for Autoimmune Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Distribution Channel, Pharmacies Distribution Channel, Drug Stores / Retail Pharmacy Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
• MIDDLE EAST
  • Autoimmune Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 173: Middle East Recent Past, Current & Future Analysis for Autoimmune Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 174: Middle East Historic Review for Autoimmune Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 175: Middle East 16-Year Perspective for Autoimmune Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
  • TABLE 176: Middle East Recent Past, Current & Future Analysis for Autoimmune Drugs by Therapy Area - Rheumatoid Arthritis, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Therapy Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: Middle East Historic Review for Autoimmune Drugs by Therapy Area - Rheumatoid Arthritis, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Therapy Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 178: Middle East 16-Year Perspective for Autoimmune Drugs by Therapy Area - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Therapy Areas for the Years 2014, 2025 & 2030
  • TABLE 179: Middle East Recent Past, Current & Future Analysis for Autoimmune Drugs by Distribution Channel - Hospitals Distribution Channel, Pharmacies Distribution Channel, Drug Stores / Retail Pharmacy Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Middle East Historic Review for Autoimmune Drugs by Distribution Channel - Hospitals Distribution Channel, Pharmacies Distribution Channel, Drug Stores / Retail Pharmacy Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 181: Middle East 16-Year Perspective for Autoimmune Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Distribution Channel, Pharmacies Distribution Channel, Drug Stores / Retail Pharmacy Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
• IRAN
  • TABLE 182: Iran Recent Past, Current & Future Analysis for Autoimmune Drugs by Therapy Area - Rheumatoid Arthritis, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Therapy Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Iran Historic Review for Autoimmune Drugs by Therapy Area - Rheumatoid Arthritis, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Therapy Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 184: Iran 16-Year Perspective for Autoimmune Drugs by Therapy Area - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Therapy Areas for the Years 2014, 2025 & 2030
  • TABLE 185: Iran Recent Past, Current & Future Analysis for Autoimmune Drugs by Distribution Channel - Hospitals Distribution Channel, Pharmacies Distribution Channel, Drug Stores / Retail Pharmacy Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Iran Historic Review for Autoimmune Drugs by Distribution Channel - Hospitals Distribution Channel, Pharmacies Distribution Channel, Drug Stores / Retail Pharmacy Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 187: Iran 16-Year Perspective for Autoimmune Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Distribution Channel, Pharmacies Distribution Channel, Drug Stores / Retail Pharmacy Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
• ISRAEL
  • TABLE 188: Israel Recent Past, Current & Future Analysis for Autoimmune Drugs by Therapy Area - Rheumatoid Arthritis, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Therapy Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Israel Historic Review for Autoimmune Drugs by Therapy Area - Rheumatoid Arthritis, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Therapy Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 190: Israel 16-Year Perspective for Autoimmune Drugs by Therapy Area - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Therapy Areas for the Years 2014, 2025 & 2030
  • TABLE 191: Israel Recent Past, Current & Future Analysis for Autoimmune Drugs by Distribution Channel - Hospitals Distribution Channel, Pharmacies Distribution Channel, Drug Stores / Retail Pharmacy Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Israel Historic Review for Autoimmune Drugs by Distribution Channel - Hospitals Distribution Channel, Pharmacies Distribution Channel, Drug Stores / Retail Pharmacy Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 193: Israel 16-Year Perspective for Autoimmune Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Distribution Channel, Pharmacies Distribution Channel, Drug Stores / Retail Pharmacy Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
• SAUDI ARABIA
  • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Autoimmune Drugs by Therapy Area - Rheumatoid Arthritis, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Therapy Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Saudi Arabia Historic Review for Autoimmune Drugs by Therapy Area - Rheumatoid Arthritis, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Therapy Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 196: Saudi Arabia 16-Year Perspective for Autoimmune Drugs by Therapy Area - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Therapy Areas for the Years 2014, 2025 & 2030
  • TABLE 197: Saudi Arabia Recent Past, Current & Future Analysis for Autoimmune Drugs by Distribution Channel - Hospitals Distribution Channel, Pharmacies Distribution Channel, Drug Stores / Retail Pharmacy Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Saudi Arabia Historic Review for Autoimmune Drugs by Distribution Channel - Hospitals Distribution Channel, Pharmacies Distribution Channel, Drug Stores / Retail Pharmacy Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 199: Saudi Arabia 16-Year Perspective for Autoimmune Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Distribution Channel, Pharmacies Distribution Channel, Drug Stores / Retail Pharmacy Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 200: UAE Recent Past, Current & Future Analysis for Autoimmune Drugs by Therapy Area - Rheumatoid Arthritis, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Therapy Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: UAE Historic Review for Autoimmune Drugs by Therapy Area - Rheumatoid Arthritis, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Therapy Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 202: UAE 16-Year Perspective for Autoimmune Drugs by Therapy Area - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Therapy Areas for the Years 2014, 2025 & 2030
  • TABLE 203: UAE Recent Past, Current & Future Analysis for Autoimmune Drugs by Distribution Channel - Hospitals Distribution Channel, Pharmacies Distribution Channel, Drug Stores / Retail Pharmacy Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: UAE Historic Review for Autoimmune Drugs by Distribution Channel - Hospitals Distribution Channel, Pharmacies Distribution Channel, Drug Stores / Retail Pharmacy Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 205: UAE 16-Year Perspective for Autoimmune Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Distribution Channel, Pharmacies Distribution Channel, Drug Stores / Retail Pharmacy Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Autoimmune Drugs by Therapy Area - Rheumatoid Arthritis, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Therapy Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Rest of Middle East Historic Review for Autoimmune Drugs by Therapy Area - Rheumatoid Arthritis, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Therapy Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 208: Rest of Middle East 16-Year Perspective for Autoimmune Drugs by Therapy Area - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Therapy Areas for the Years 2014, 2025 & 2030
  • TABLE 209: Rest of Middle East Recent Past, Current & Future Analysis for Autoimmune Drugs by Distribution Channel - Hospitals Distribution Channel, Pharmacies Distribution Channel, Drug Stores / Retail Pharmacy Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Rest of Middle East Historic Review for Autoimmune Drugs by Distribution Channel - Hospitals Distribution Channel, Pharmacies Distribution Channel, Drug Stores / Retail Pharmacy Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 211: Rest of Middle East 16-Year Perspective for Autoimmune Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Distribution Channel, Pharmacies Distribution Channel, Drug Stores / Retail Pharmacy Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
• AFRICA
  • Autoimmune Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 212: Africa Recent Past, Current & Future Analysis for Autoimmune Drugs by Therapy Area - Rheumatoid Arthritis, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Therapy Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Africa Historic Review for Autoimmune Drugs by Therapy Area - Rheumatoid Arthritis, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Therapy Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 214: Africa 16-Year Perspective for Autoimmune Drugs by Therapy Area - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Therapy Areas for the Years 2014, 2025 & 2030
  • TABLE 215: Africa Recent Past, Current & Future Analysis for Autoimmune Drugs by Distribution Channel - Hospitals Distribution Channel, Pharmacies Distribution Channel, Drug Stores / Retail Pharmacy Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Africa Historic Review for Autoimmune Drugs by Distribution Channel - Hospitals Distribution Channel, Pharmacies Distribution Channel, Drug Stores / Retail Pharmacy Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 217: Africa 16-Year Perspective for Autoimmune Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Distribution Channel, Pharmacies Distribution Channel, Drug Stores / Retail Pharmacy Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030

IV. COMPETITION